Immunocore’s Kimmtrak Gets FDA Approval as First Treatment for Rare Eye Cancer and First T Cell Receptor Therapeutic
XTalks
JANUARY 28, 2022
Uveal melanoma is a rare and aggressive type of melanoma of the eye. Up to 50 percent of patients will develop metastatic disease, mainly spreading to the liver, making treatment difficult and limited. The new treatment will thus help address the unmet need for the disease. The median treatment time is about 23 weeks (or 5.3
Let's personalize your content